ArticleHemaSphere2021
Azacytidine Treatment for VEXAS Syndrome.
Article in HemaSphere, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Assessing the efficacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysis.Bone marrow transplantation · 2024Pooled it
- Trial
- Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.American journal of hematology · 2026Article
- VEXAS syndrome.Nature reviews. Disease primers · 2026Review
- Clinical-Pathological Conference Series from the Medical University of Graz : Case No 183: A 57-year-old farmer with fever, cough, maculopapular rash and bicytopenia.Wiener klinische Wochenschrift · 2026Article
- The First Reported Case of VEXAS Syndrome in Lebanon: Efficacy of Azacitidine as a Therapeutic Option-Case Report.Case reports in hematology · 2026Article
- UBA1 as a proteostasis-innate immunity checkpoint: lessons from vexas syndrome and therapeutic implications.Frontiers in immunology · 2026Review
- VEXAS syndrome.International journal of hematology · 2025Review
- Prevalence and outcome of VEXAS syndrome in unrelated hematopoietic cell transplantation for bone marrow failure.Clinical and experimental medicine · 2025Article
- Very long-term remission with azacitidine in VEXAS syndrome.Haematologica · 2025Article
- Promise of Jak Inhibition in the Management of VEXAS, Case Report with Review of the Literature.Open access rheumatology : research and reviews · 2025Article
- Case report: VEXAS syndrome with excellent response to treatment with azacitidine.Annals of hematology · 2024Article
- VEXAS Syndrome: A Comprehensive Review of Current Therapeutic Strategies and Emerging Treatments.Journal of clinical medicine · 2024Review
- De-escalation of corticosteroids and clonal remission inHaematologica · 2024Article
- Review
- Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome.HemaSphere · 2024Article
- Ocular and orbital manifestations in VEXAS syndrome.Eye (London, England) · 2024Article
- VEXAS syndrome: complete molecular remission after hypomethylating therapy.Annals of hematology · 2024Article
- Autoimmunity and Autoinflammation: Relapsing Polychondritis and VEXAS Syndrome Challenge.International journal of molecular sciences · 2024Review
- VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.